Active Clinical Trials

Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.

Showing 188 results
  • Sort by
  • Study title
  • Condition
  • Phase
  • Location
Study title Condition Phase Location

A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A.

 		Charcot-Marie-Tooth Disease, Type 1A Phase1 Canada NCT07140614

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

 		Progressive Metastatic Castrate Resistant Prostate Cancer Phase1, Phase2 Australia
Singapore 		NCT07206056

CINC424A2X01B Rollover Protocol

 		Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia, Thalassemia Phase4 South Korea NCT02386800

Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease

 		Graft vs. Host Disease, Chronic Graft vs. Host Disease, Corticosteroid-refractory Chronic Graft vs. Host Disease Phase4 China NCT06824103

Concept Elicitation and Patient Experience Mapping in SA-AKI

 		Sepsis-associated Acute Kidney Injury United States NCT07180238

RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia

 		HR+/HER2- Early Breast Cancer Saudi Arabia NCT06797531

A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.

 		Autoimmune and Chronic Inflammatory Diseases Phase1 United States NCT07032272

NIS PDC the Efficacy and Safety of Iptacopan in Adults in Routine Clinical Practice

 		Paroxysmal Nocturnal Hemoglobinuria Russia NCT07036718

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

 		Relapsing Multiple Sclerosis Phase3 Australia
Canada
South Africa 		NCT06846281

Pelacarsen Roll-over Extension Program

 		Atherosclerotic Cardiovascular Disease Phase3 United States NCT06875973